

Lynch Syndrome: *MSH6* Mutations

What you should know about Lynch syndrome (*MSH6* Mutations)

Lynch syndrome is the most common type of hereditary colon cancer and accounts for 2-4% of all colon cancers. Families with Lynch syndrome often have multiple family members with colon, uterine or other cancers, typically diagnosed before age 50. Lynch syndrome is caused by mutations in one of five different genes, and the specific cancer risks and management recommendations depend on the gene.

Cancer risks associated with Lynch syndrome (*MSH6* mutations)

Males and females with an *MSH6* gene mutation have a 15-44% risk to develop colorectal cancer in their lifetime. Females have a 17-46% risk for uterine cancer, and a 1-11% risk for ovarian cancer. Males and females with an *MSH6* mutation may also have an increased risk for other types of cancer including stomach, small bowel, urothelial, and bladder. These cancers tend to occur at a younger age.

Risks to family members

Mutations in the *MSH6* gene are inherited in an autosomal dominant fashion. This means that children, brothers, sisters, and parents of individuals with an *MSH6* mutation have a 1 in 2 (50%) chance of having the mutation as well. Individuals with an *MSH6* mutation may develop one cancer, more than one cancer, or none at all. Both males and females can inherit a familial *MSH6* mutation and can pass that it on to their children.

When an individual inherits two *MSH6* mutations (one from each parent), this causes a syndrome called Constitutional Mismatch Repair Deficiency (CMMRD). CMMRD is associated with an increased risk for childhood colon cancer, lymphoma, brain tumors, and cafe au lait spots.

Managing cancer risks

The following surveillance is recommended by the National Comprehensive Cancer Network (v3.2019):

Colon Cancer

- Colonoscopy every 1-2 years starting at age 20-25 or 2-5 years prior to earliest colon cancer diagnosis in the family, whichever comes first.
- If colon cancer is detected, partial or complete removal of colon should be considered

Uterine/Ovarian Cancer

- Screening via uterine biopsy every 1-2 years and transvaginal ultrasound may be considered
- CA-125 screening and transvaginal ultrasound can be considered (these tests have limited ability for early detection of ovarian cancer)
- Removal of the uterus after childbearing is complete can be considered to reduce risk. There is currently insufficient evidence to make a specific recommendation regarding risk-reducing removal of the ovaries and fallopian tubes based on the presence of an *MSH6* mutation

Other Cancers

- Annual physical examination/neurological exam starting at age 25-30
- Annual urinalysis beginning at age 30-35
- Consider upper endoscopy every 3-5 years, beginning at age 40
- Additional screenings may be considered based on personal risk factors and family history

Last updated 1/2/2020